Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neurofibromatoses × cabozantinib × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Brain Neoplasms 7 Glioblastoma 3 Carcinoma, Renal Cell 3 Neurofibroma, Plexiform 2 Glioma 2 Central Nervous System Neoplasms 2 Carcinoma, Medullary 2 Astrocytoma 2 Wilms Tumor 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Pheochromocytoma 1 Paraganglioma, Extra-Adrenal 1 Paraganglioma 1 Osteosarcoma 1 Neurofibromatosis 1 1 Neurofibromatoses 1 Neuroendocrine Tumors 1 Neuroblastoma 1 Meningioma 1 Melanoma 1 Lung Neoplasms 1 Gliosarcoma 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

mirdametinib 3 Surveys and Questionnaires 2 Imatinib Mesylate 2 tipifarnib 1 talimogene laherparepvec 1 pirfenidone 1 nilotinib 1 emvododstat 1 diphenylcyclopropenone 1 cabozantinib 1 binimetinib 1 Sunitinib 1 Sirolimus 1 Sevoflurane 1 Propofol 1 Percutaneous Collagen Induction 1 Nitrous Oxide 1 Magnetic Resonance Spectroscopy 1 Lidocaine 1 Lasers, Solid-State 1 Lasers 1 Glycopyrrolate 1 Dexmedetomidine 1 Aminolevulinic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02101736 2023-05-24

NF105-CABO

University of Alabama at Birmingham

Phase 2 Completed

45 enrolled 10 charts

Neurofibromatoses, Neurofibroma, Plexiform

Data powered by HemOnc (CC BY 4.0) Colophon ⚡